Hospital
Memorial Hospital at Gulfport
Memorial Hospital at Gulfport was paid $87.40M by Medicaid between Jan 2018 and Dec 2024, across 577 billing codes. Its largest line is 99284, emergency room visit (serious) — 8.8% of everything it billed.
33Billing provider infoMEMORIAL HOSPITAL AT GULFPORT
GULFPORT, MS 39501
GULFPORT, MS 39501
33aNPI1073606901assigned 10/02/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$87.40M
24GClaims2,864,898
24DCodes billed577
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Mississippi
Rank by total paid#3 of 77
Median peer was paid$8.23M
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 395,032 | $12.16M | |
| 2019 | 374,999 | $11.26M | |
| 2020 | 340,787 | $9.46M | |
| 2021 | 451,360 | $14.10M | |
| 2022 | 468,578 | $15.18M | |
| 2023 | 452,071 | $13.85M | |
| 2024incomplete | 382,071 | $11.38M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.8% | 44,577 | 36,827 | $7.67M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.3% | 48,786 | 41,151 | $6.42M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.8% | 27,144 | 21,773 | $5.07M |
| G0378 | Hospital observation service, per hour | 4.9% | 12,636 | 9,054 | $4.28M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.0% | 62,992 | 49,835 | $3.53M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.6% | 83,673 | 66,271 | $3.12M |
| J9271 | Injection, pembrolizumab, 1 mg | 3.5% | 806 | 514 | $3.08M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 3.2% | 11,853 | 10,113 | $2.81M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.1% | 29,304 | 22,927 | $2.74M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.0% | 25,640 | 16,298 | $1.76M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.9% | 20,503 | 11,705 | $1.64M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.8% | 11,934 | 5,656 | $1.59M |
565 more codes
| 93458 | 1.6% | 2,233 | $1.41M | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.5% | 126,691 | $1.27M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.4% | 8,880 | $1.18M |
| 99204 | Doctor's office visit, new patient (more involved) | 1.3% | 15,530 | $1.15M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.3% | 3,596 | $1.10M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.2% | 4,857 | $1.01M |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | 1.1% | 404 | $973K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.1% | 15,319 | $969K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.1% | 28,607 | $966K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 7,893 | $954K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.0% | 9,039 | $913K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.0% | 51,165 | $906K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 2,722 | $860K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 24,371 | $850K |
| 80053 | Comprehensive metabolic panel | <1% | 130,730 | $749K |
| 71045 | Radiologic examination, chest; single view | <1% | 27,498 | $718K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 1,781 | $707K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 30,435 | $685K |
| J0897 | Injection, denosumab, 1 mg | <1% | 1,211 | $654K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 7,558 | $635K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 11,577 | $587K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 16,774 | $564K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,816 | $562K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 152,204 | $559K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 12,829 | $516K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 11,700 | $504K |
| 20610 | <1% | 4,982 | $502K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 15,057 | $496K |
| 86885 | <1% | 7,711 | $476K | |
| 87507 | <1% | 1,975 | $457K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 5,927 | $454K |
| 36415 | Collection of venous blood by venipuncture | <1% | 213,383 | $438K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 1,730 | $376K |
| 86900 | <1% | 7,838 | $367K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 317 | $365K |
| 87428 | <1% | 6,941 | $359K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 11,779 | $352K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 4,109 | $351K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 31,459 | $350K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,269 | $322K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,195 | $321K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 3,244 | $301K |
| 87486 | <1% | 11,711 | $290K | |
| 87581 | <1% | 11,712 | $288K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 7,990 | $280K |
| 83880 | <1% | 20,609 | $279K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,754 | $275K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 33,566 | $256K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,567 | $241K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 3,211 | $233K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 1,032 | $218K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,480 | $215K |
| 99205 | Prolong outpt/office vis | <1% | 2,195 | $211K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,895 | $211K |
| 93017 | <1% | 3,938 | $206K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 10,295 | $184K |
| 93970 | <1% | 2,989 | $183K | |
| 80061 | Lipid panel | <1% | 34,045 | $182K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 815 | $179K |
| 99490 | Ccm add 20min | <1% | 13,241 | $179K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,439 | $173K |
| 36430 | <1% | 1,919 | $172K | |
| 73630 | <1% | 4,732 | $164K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 14,099 | $163K |
| 72100 | <1% | 3,788 | $163K | |
| 73560 | <1% | 5,384 | $162K | |
| 97602 | <1% | 3,121 | $159K | |
| 96367 | <1% | 5,347 | $158K | |
| 94060 | <1% | 2,356 | $152K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 3,202 | $151K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,513 | $147K |
| 84484 | <1% | 30,093 | $144K | |
| 93880 | <1% | 2,722 | $141K | |
| 73130 | <1% | 3,990 | $140K | |
| 76801 | <1% | 1,997 | $140K | |
| 73030 | <1% | 4,702 | $139K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,159 | $137K |
| 94726 | <1% | 2,350 | $135K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 31,673 | $132K |
| 73610 | <1% | 3,738 | $131K | |
| 87088 | <1% | 28,409 | $130K | |
| 86901 | <1% | 7,808 | $124K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,220 | $123K |
| 64493 | <1% | 545 | $120K | |
| 71250 | <1% | 3,805 | $119K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,697 | $117K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,391 | $116K |
| 74018 | <1% | 2,934 | $113K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,702 | $110K |
| 72141 | <1% | 1,377 | $110K | |
| 74022 | <1% | 2,119 | $109K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,863 | $106K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 6,010 | $105K |
| 73110 | <1% | 2,915 | $103K | |
| 77334 | <1% | 479 | $102K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,265 | $102K |
| 36600 | <1% | 3,475 | $102K | |
| 43248 | <1% | 668 | $101K | |
| 96416 | <1% | 865 | $100K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 8,921 | $98K |
| 95913 | <1% | 586 | $95K | |
| 84703 | <1% | 18,085 | $94K | |
| 86923 | <1% | 1,291 | $94K | |
| 82948 | <1% | 38,512 | $94K | |
| 81001 | <1% | 54,372 | $94K | |
| 76770 | <1% | 2,074 | $91K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,365 | $89K |
| 82553 | <1% | 18,710 | $89K | |
| 74178 | <1% | 911 | $87K | |
| 95912 | <1% | 524 | $86K | |
| 96415 | <1% | 2,810 | $86K | |
| 88307 | <1% | 719 | $85K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 26,267 | $84K |
| 73502 | <1% | 3,470 | $82K | |
| 96417 | <1% | 3,029 | $81K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 414 | $80K |
| 82805 | <1% | 2,956 | $78K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 5,196 | $72K |
| 85730 | <1% | 24,578 | $71K | |
| 77336 | <1% | 1,510 | $71K | |
| 76536 | <1% | 1,618 | $70K | |
| 82550 | <1% | 22,341 | $69K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 2,489 | $69K |
| 77300 | <1% | 280 | $68K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,046 | $67K |
| 93925 | <1% | 1,356 | $66K | |
| 85610 | <1% | 31,643 | $65K | |
| 87186 | <1% | 11,222 | $65K | |
| 95117 | <1% | 3,051 | $64K | |
| 72040 | <1% | 1,906 | $63K | |
| 86235 | <1% | 1,832 | $63K | |
| 93971 | <1% | 1,879 | $61K | |
| 82728 | <1% | 10,246 | $60K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,008 | $60K |
| 64483 | <1% | 211 | $58K | |
| 87040 | <1% | 11,218 | $57K | |
| 83690 | <1% | 15,160 | $57K | |
| 59025 | Fetal non-stress test | <1% | 533 | $56K |
| 97597 | <1% | 1,221 | $55K | |
| 83735 | <1% | 18,980 | $55K | |
| 82607 | <1% | 8,135 | $53K | |
| 86756 | <1% | 4,359 | $52K | |
| 73590 | <1% | 1,435 | $50K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 407 | $49K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 652 | $47K |
| 64616 | <1% | 219 | $47K | |
| 73562 | <1% | 1,612 | $47K | |
| 76642 | <1% | 1,594 | $47K | |
| 96411 | <1% | 1,420 | $44K | |
| 85027 | <1% | 13,154 | $44K | |
| 84439 | <1% | 9,671 | $42K | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 36 | $41K |
| 88304 | <1% | 1,423 | $41K | |
| 86318 | <1% | 3,611 | $41K | |
| 72110 | <1% | 959 | $41K | |
| 84702 | <1% | 3,867 | $40K | |
| 95813 | <1% | 364 | $40K | |
| 83605 | <1% | 9,065 | $39K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,181 | $38K |
| 70486 | <1% | 855 | $38K | |
| 72114 | <1% | 937 | $37K | |
| 96401 | <1% | 1,284 | $37K | |
| 93922 | <1% | 1,227 | $37K | |
| 86803 | <1% | 4,674 | $37K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 372 | $34K |
| 83655 | <1% | 3,546 | $34K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,071 | $33K |
| 82075 | <1% | 1,801 | $33K | |
| 72131 | <1% | 949 | $32K | |
| 83520 | <1% | 3,312 | $32K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,864 | $31K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 428 | $31K |
| 87070 | <1% | 5,086 | $31K | |
| 86780 | <1% | 3,649 | $29K | |
| 87340 | <1% | 5,196 | $29K | |
| 77412 | <1% | 362 | $28K | |
| 73090 | <1% | 714 | $27K | |
| 77066 | Tomosynthesis, mammo | <1% | 538 | $27K |
| 83970 | <1% | 2,088 | $27K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,541 | $26K |
| 77386 | <1% | 130 | $26K | |
| 74019 | <1% | 485 | $26K | |
| 95816 | <1% | 274 | $26K | |
| 87807 | <1% | 2,399 | $24K | |
| 86481 | <1% | 601 | $24K | |
| 83540 | <1% | 8,782 | $23K | |
| 73070 | <1% | 659 | $23K | |
| 80305 | <1% | 3,220 | $23K | |
| 82746 | <1% | 3,517 | $23K | |
| 52000 | <1% | 137 | $22K | |
| 92557 | <1% | 262 | $21K | |
| 81025 | <1% | 3,720 | $21K | |
| 70491 | <1% | 243 | $21K | |
| 82784 | <1% | 2,296 | $20K | |
| 86704 | <1% | 2,956 | $19K | |
| 86038 | <1% | 3,521 | $19K | |
| 12001 | <1% | 189 | $19K | |
| 12011 | <1% | 203 | $19K | |
| 96523 | <1% | 1,207 | $19K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 700 | $19K |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | <1% | 25 | $18K |
| 64615 | <1% | 126 | $18K | |
| 86140 | <1% | 6,428 | $18K | |
| 84481 | <1% | 2,295 | $18K | |
| 83550 | <1% | 4,996 | $18K | |
| 86708 | <1% | 2,386 | $17K | |
| 85378 | <1% | 3,829 | $17K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 23,321 | $17K |
| 93296 | <1% | 1,644 | $16K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 2,439 | $16K |
| 94010 | <1% | 448 | $16K | |
| 93351 | <1% | 117 | $16K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,713 | $15K |
| 86160 | <1% | 1,962 | $15K | |
| 71101 | <1% | 331 | $15K | |
| 80076 | <1% | 2,773 | $14K | |
| 85652 | <1% | 11,317 | $14K | |
| 81003 | <1% | 10,055 | $14K | |
| 88112 | <1% | 591 | $13K | |
| 73565 | <1% | 543 | $13K | |
| 82570 | <1% | 5,901 | $13K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 626 | $13K |
| 86376 | <1% | 2,164 | $13K | |
| 90686 | <1% | 1,310 | $13K | |
| 82077 | <1% | 1,470 | $13K | |
| 87480 | <1% | 1,047 | $12K | |
| 97165 | <1% | 681 | $12K | |
| 87660 | <1% | 995 | $12K | |
| 72070 | <1% | 286 | $12K | |
| 83883 | <1% | 1,696 | $12K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 678 | $12K |
| 72050 | <1% | 260 | $12K | |
| 87510 | <1% | 1,050 | $11K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 65 | $11K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 255 | $11K |
| 10061 | <1% | 60 | $11K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 156 | $11K |
| 87205 | <1% | 4,125 | $11K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 1,463 | $11K |
| 62323 | <1% | 110 | $10K | |
| 82951 | <1% | 1,511 | $10K | |
| 80069 | <1% | 3,259 | $10K | |
| 86762 | <1% | 1,214 | $10K | |
| 36573 | <1% | 24 | $10K | |
| J7325 | Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg | <1% | 111 | $10K |
| 82042 | <1% | 3,627 | $10K | |
| 73523 | <1% | 183 | $10K | |
| 82247 | <1% | 2,668 | $10K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 4,233 | $10K |
| 72158 | <1% | 76 | $9K | |
| 73552 | <1% | 273 | $9K | |
| 84403 | <1% | 895 | $9K | |
| 99495 | <1% | 882 | $9K | |
| 86225 | <1% | 1,648 | $9K | |
| 87493 | <1% | 504 | $9K | |
| 84153 | <1% | 1,546 | $9K | |
| 86769 | <1% | 467 | $8K | |
| 72170 | <1% | 177 | $8K | |
| 73221 | <1% | 93 | $8K | |
| 86431 | <1% | 3,192 | $8K | |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 968 | $8K |
| 82962 | <1% | 4,489 | $8K | |
| 86300 | <1% | 854 | $8K | |
| 82565 | <1% | 2,609 | $8K | |
| 80143 | <1% | 633 | $7K | |
| 97161 | <1% | 357 | $7K | |
| 62321 | <1% | 44 | $7K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 14 | $7K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 111 | $7K |
| G0008 | Administration of influenza virus vaccine | <1% | 2,239 | $7K |
| 73700 | <1% | 189 | $7K | |
| 71271 | <1% | 195 | $7K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,788 | $7K |
| 82150 | <1% | 1,747 | $7K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 12 | $6K |
| 87522 | Neg quan hep c or qual rna | <1% | 230 | $6K |
| 36416 | <1% | 34,970 | $6K | |
| 93225 | <1% | 177 | $6K | |
| 96402 | <1% | 291 | $6K | |
| J2770 | Injection, quinupristin/dalfopristin, 500 mg (150/350) | <1% | 71 | $6K |
| 0002A | <1% | 291 | $6K | |
| 73140 | <1% | 122 | $6K | |
| 84156 | <1% | 3,818 | $6K | |
| 90662 | <1% | 555 | $5K | |
| 82043 | <1% | 2,178 | $5K | |
| 12002 | <1% | 63 | $5K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 17,121 | $5K |
| 87536 | <1% | 149 | $5K | |
| 92567 | <1% | 233 | $5K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 31,768 | $5K |
| 82803 | <1% | 378 | $5K | |
| 93226 | <1% | 174 | $5K | |
| 72052 | <1% | 133 | $5K | |
| 92610 | <1% | 264 | $5K | |
| 80179 | <1% | 414 | $5K | |
| 84100 | <1% | 2,374 | $5K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 388 | $5K |
| 86200 | <1% | 801 | $5K | |
| 84165 | <1% | 1,491 | $5K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 1,490 | $5K |
| 82378 | <1% | 616 | $5K | |
| 80164 | <1% | 572 | $5K | |
| 84550 | <1% | 2,482 | $4K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 207 | $4K |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 1,574 | $4K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 17,365 | $4K |
| 87150 | <1% | 177 | $4K | |
| 29581 | <1% | 82 | $4K | |
| 87641 | <1% | 410 | $4K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 539 | $4K |
| 86039 | <1% | 816 | $4K | |
| 43235 | <1% | 18 | $4K | |
| 86706 | <1% | 634 | $4K | |
| 73080 | <1% | 97 | $4K | |
| 96376 | <1% | 7,850 | $4K | |
| 93242 | <1% | 297 | $4K | |
| 82248 | <1% | 1,175 | $4K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 596 | $4K |
| 0001A | <1% | 334 | $4K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 37 | $4K |
| 29125 | <1% | 89 | $3K | |
| 80047 | <1% | 498 | $3K | |
| 11721 | <1% | 185 | $3K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 8,709 | $3K |
| 86360 | <1% | 136 | $3K | |
| 97116 | <1% | 965 | $3K | |
| 85045 | <1% | 1,532 | $3K | |
| 94375 | <1% | 30 | $3K | |
| 86592 | <1% | 1,177 | $3K | |
| 77290 | <1% | 15 | $3K | |
| 87640 | <1% | 411 | $3K | |
| 31720 | <1% | 18 | $3K | |
| 73564 | <1% | 80 | $3K | |
| 87210 | <1% | 837 | $3K | |
| 83516 | <1% | 311 | $3K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 7,640 | $3K |
| 87081 | <1% | 716 | $3K | |
| 84520 | <1% | 852 | $3K | |
| 72146 | <1% | 40 | $3K | |
| 93660 | <1% | 12 | $3K | |
| 83615 | <1% | 950 | $3K | |
| 84146 | <1% | 185 | $3K | |
| 97162 | <1% | 151 | $2K | |
| 82105 | <1% | 356 | $2K | |
| 82140 | <1% | 413 | $2K | |
| 86334 | <1% | 381 | $2K | |
| 90732 | <1% | 104 | $2K | |
| 10060 | <1% | 25 | $2K | |
| 29515 | <1% | 37 | $2K | |
| 76830 | Ultrasound, transvaginal | <1% | 34 | $2K |
| 84132 | <1% | 1,065 | $2K | |
| 82947 | <1% | 740 | $2K | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 179 | $2K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 29 | $2K |
| 86480 | <1% | 47 | $2K | |
| 85018 | <1% | 1,327 | $2K | |
| 88173 | <1% | 41 | $2K | |
| 82085 | <1% | 424 | $2K | |
| 99496 | <1% | 166 | $2K | |
| 87077 | <1% | 321 | $2K | |
| 31231 | <1% | 15 | $2K | |
| 86787 | <1% | 149 | $2K | |
| 99152 | <1% | 3,446 | $1K | |
| 86147 | <1% | 44 | $1K | |
| 82785 | <1% | 226 | $1K | |
| 86308 | <1% | 358 | $1K | |
| 86355 | <1% | 76 | $1K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 179 | $1K |
| 83013 | <1% | 27 | $1K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 793 | $1K |
| 86357 | <1% | 76 | $1K | |
| 88342 | <1% | 34 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,646 | $1K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,536 | $1K |
| 80299 | <1% | 127 | $1K | |
| 90674 | <1% | 129 | $1K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 4,835 | $1K |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 741 | $1K |
| 72072 | <1% | 28 | $1K | |
| 84402 | <1% | 81 | $1K | |
| 87449 | <1% | 195 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 4,713 | $1K |
| 93299 | <1% | 101 | $1K | |
| 87116 | <1% | 198 | $1K | |
| 76981 | <1% | 113 | $1K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 3,673 | $1K |
| 96377 | <1% | 44 | $973.32 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 264 | $930.52 |
| 80202 | <1% | 111 | $911.80 | |
| 70496 | <1% | 15 | $905.59 | |
| 90473 | <1% | 17 | $850.20 | |
| 0003A | <1% | 50 | $832.47 | |
| 73060 | <1% | 34 | $803.78 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 707 | $790.08 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 3,083 | $783.98 |
| 77080 | <1% | 12 | $761.40 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 7,145 | $749.83 |
| 86696 | <1% | 68 | $737.19 | |
| 93308 | <1% | 14 | $694.62 | |
| 83993 | <1% | 44 | $689.65 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 10,503 | $642.56 |
| 87101 | <1% | 183 | $624.24 | |
| 87324 | <1% | 127 | $622.70 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,448 | $616.29 |
| 87206 | <1% | 170 | $613.26 | |
| 83001 | <1% | 59 | $604.34 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 4,091 | $598.68 |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 62 | $595.66 |
| G0506 | Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) | <1% | 73 | $589.74 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 13,381 | $587.12 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 10,197 | $542.13 |
| 89051 | <1% | 130 | $535.80 | |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 19 | $523.03 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,680 | $513.51 |
| 86580 | <1% | 29 | $506.34 | |
| 82670 | <1% | 29 | $494.34 | |
| 86695 | <1% | 70 | $493.07 | |
| 83519 | <1% | 57 | $487.32 | |
| 90670 | <1% | 34 | $480.22 | |
| 94760 | <1% | 6,539 | $476.28 | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 15 | $457.95 |
| 86665 | <1% | 16 | $443.52 | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 41 | $439.10 |
| 87046 | <1% | 63 | $406.52 | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 101 | $401.94 |
| 87045 | <1% | 63 | $400.52 | |
| 86021 | <1% | 55 | $386.68 | |
| 96368 | <1% | 2,199 | $380.20 | |
| 83630 | <1% | 25 | $380.12 | |
| 93924 | <1% | 14 | $376.69 | |
| 99221 | <1% | 13 | $370.27 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 763 | $365.65 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 227 | $358.90 |
| 86663 | <1% | 38 | $345.06 | |
| 92523 | <1% | 14 | $327.22 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 1,736 | $269.89 |
| 85014 | <1% | 288 | $266.67 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 1,655 | $265.05 |
| 85347 | <1% | 91 | $239.77 | |
| 94729 | <1% | 2,342 | $224.84 | |
| 64494 | <1% | 556 | $201.42 | |
| 82533 | <1% | 29 | $200.18 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 1,807 | $200.00 |
| 85613 | <1% | 40 | $199.52 | |
| 90715 | <1% | 2,009 | $194.62 | |
| 87209 | <1% | 13 | $189.81 | |
| 82652 | <1% | 19 | $189.28 | |
| 86664 | <1% | 16 | $186.89 | |
| 82164 | <1% | 28 | $185.26 | |
| 84144 | <1% | 16 | $183.26 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 10,252 | $177.13 |
| 83020 | <1% | 31 | $173.21 | |
| 86738 | <1% | 20 | $171.54 | |
| 0296T | <1% | 13 | $159.96 | |
| 87427 | <1% | 17 | $152.98 | |
| 80051 | <1% | 51 | $148.62 | |
| 82787 | <1% | 14 | $142.14 | |
| 82103 | <1% | 33 | $138.11 | |
| 95886 | <1% | 1,301 | $130.22 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 459 | $121.99 |
| 82104 | <1% | 29 | $121.06 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 964 | $117.75 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,385 | $111.42 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 5,598 | $110.31 |
| 82272 | <1% | 60 | $109.22 | |
| 96160 | <1% | 14 | $107.59 | |
| Q9961 | High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml | <1% | 126 | $100.80 |
| 87177 | <1% | 13 | $93.97 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 68 | $88.32 |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 19 | $77.46 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,768 | $73.13 |
| 90661 | <1% | 15 | $67.32 | |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 308 | $66.00 |
| 85049 | <1% | 21 | $58.63 | |
| 82525 | <1% | 12 | $56.41 | |
| 86003 | <1% | 15 | $52.37 | |
| 84630 | <1% | 13 | $52.06 | |
| 84145 | <1% | 2,303 | $49.66 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 822 | $49.40 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 3,613 | $48.92 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 6,618 | $45.76 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,973 | $37.15 |
| 82952 | <1% | 14 | $36.30 | |
| Q2036 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval) | <1% | 66 | $36.27 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 284 | $27.72 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,575 | $23.50 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 85 | $22.07 |
| 84460 | <1% | 12 | $19.05 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 75 | $18.42 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 98 | $17.51 |
| 83721 | <1% | 13 | $13.77 | |
| G0009 | Administration of pneumococcal vaccine | <1% | 387 | $12.25 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 117 | $9.27 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 182 | $9.17 |
| 90694 | <1% | 288 | $8.71 | |
| J3490 | Unclassified drugs | <1% | 31,484 | $6.98 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 504 | $6.46 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 10,521 | $5.40 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 49 | $0.96 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 298 | $0.54 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 3,750 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 988 | $0.00 |
| 99406 | 0% | 661 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 1,021 | $0.00 |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | 0% | 92 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 189 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 1,525 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 414 | $0.00 |
| C1766 | Introducer/sheath, guiding, intracardiac electrophysiological, steerable, other than peel-away | 0% | 1,789 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 748 | $0.00 |
| C1769 | Guide wire | 0% | 4,932 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 278 | $0.00 |
| 88311 | 0% | 226 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 2,913 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 197 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 190 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 1,711 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 2,200 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 1,833 | $0.00 |
| 80050 | General health panel | 0% | 211 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 250 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 1,202 | $0.00 |
| 88341 | 0% | 15 | $0.00 | |
| 77001 | 0% | 447 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 24 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 166 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 397 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 109 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 982 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 253 | $0.00 |
| J1250 | Injection, dobutamine hydrochloride, per 250 mg | 0% | 13 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 293 | $0.00 |
| 99439 | 0% | 177 | $0.00 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 46 | $0.00 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 24 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 523 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 55 | $0.00 |
| C9600 | Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch | 0% | 15 | $0.00 |
| 90677 | 0% | 14 | $0.00 | |
| 64484 | 0% | 21 | $0.00 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 24 | $0.00 |
| 80320 | 0% | 66 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 4,250 | $0.00 |
| A9505 | Thallium tl-201 thallous chloride, diagnostic, per millicurie | 0% | 1,874 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 397 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 2,121 | $0.00 |
| J2950 | Injection, promazine hcl, up to 25 mg | 0% | 216 | $0.00 |
| C1757 | Catheter, thrombectomy/embolectomy | 0% | 19 | $0.00 |
| 64495 | 0% | 233 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 1,237 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 524 | $0.00 |
| 77387 | 0% | 101 | $0.00 | |
| C1874 | Stent, coated/covered, with delivery system | 0% | 148 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 2,446 | $0.00 |
| 76937 | 0% | 154 | $0.00 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 82 | $0.00 |
| 93325 | 0% | 286 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 346 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 225 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 304 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 76 | $0.00 |
| 90653 | 0% | 19 | $0.00 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 35 | $0.00 |
| Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | 0% | 57 | $0.00 |
| 99244 | Office or other outpatient consultation, moderate to high complexity | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNICAUD, KENT (CEO)